Global Hepatocellular Carcinoma (HCC) Market Opportunities Pointed Out by GlobalData in Its Report Recently Published at MarketPublishers.com
08 Apr 2016 • by Natalie Aster
LONDON – Nowadays, hepatocellular carcinoma (HCC) is recognised as the major form of liver cancer; it accounts for an 85% share of total number of liver cancer cases. The results of HCC treatment and the prognosis depend on the stage, at which the disease is diagnosed. Unfortunately, even with such existing treatment options as surgical resection, ablative therapies and liver transplantation, which are only suitable for early-stage patients, the biggest part of patients is likely to progress to further advanced stages of the disease.
Presently, the global HCC market is driven mainly by the urgent necessity to introduce second-line treatments for patients with advanced HCC. The further market growth will likely be supported by rising HCC incidence together with increasing number of elderly population.
The in-demand research report “OpportunityAnalyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024” worked out by GlobalData includes a detailed analysis of the global hepatocellular carcinoma (HCC) and a granular overview of the key existing HCC treatment options. It contains major details on the disease like epidemiology, etiology, pathophysiology, symptoms of HCC, etc. Moreover, the research publication points out the major unmet needs, examines future market opportunities, contains an insightful review of the key industry drivers, restraints and challenges. Furthermore, the report provides a pipeline assessment and a snapshot of R&D activities.
OpportunityAnalyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024
Published: December, 2015
Price: US$ 9,495.00
Other comprehensive research reports by our market research partner can be found at GlobalData page.